Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833415 · ClinicalTrials.gov registry record · Phase 4
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02833415 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT02833415, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional studies of glycerol metabolism in hepatic gluconeogenesis using a well-validated nuclear magnetic resonance (NMR) spectroscopy platform.
Interventions
- DRUG Empagliflozin
- DRUG [U-13C3] glycerol
- DRUG Placebo (for Empagliflozin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833415
The ClinicalTrials.gov registry entry for NCT02833415 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Empagliflozin is the first listed.
NCT02833415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833415 about?
NCT02833415 is a clinical study titled "Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging". This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional studies of glycerol metaboli...
What is the current status of trial NCT02833415?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02833415?
The interventions under investigation include: Empagliflozin (DRUG), [U-13C3] glycerol (DRUG), Placebo (for Empagliflozin) (DRUG).
Who is sponsoring clinical trial NCT02833415?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.